10-Q: Citius Oncology Reports First LYMPHIR Revenue, Narrows Loss

Citius Oncology, Inc. reported its first revenue from LYMPHIR sales in Q1 2026, significantly narrowing its net loss, but faces ongoing going concern doubts and a need for further capital.

Summary

• Citius Oncology, Inc. (CTOR) reported its first revenue of $3,944,111 for the three months ended December 31, 2025, following the commercial launch of LYMPHIR in December 2025.
• The company achieved a gross profit of $3,154,903, representing an approximate 80% gross profit margin on net product revenues.
• Net loss for the quarter decreased to $5,534,069, an improvement from a net loss of $6,659,205 in the same period last year.
• Cash and cash equivalents increased to $7,295,451 as of December 31, 2025, up from $3,924,908 on September 30, 2025, primarily due to a $15.1 million net proceeds from a December 2025 equity offering.
• Despite the revenue generation and capital raise, the company has a negative working capital of approximately $7.6 million and an accumulated deficit of $69,574,025.
• Management expressed substantial doubt about the company's ability to continue as a going concern beyond May 2026 without raising additional capital.
• A $18.25 million balance of a $27.5 million milestone payment remains due to Dr. Reddys, with a partial deferral agreed upon without penalty.
• The company has significant minimum purchase commitments for drug substance and finished drug products totaling approximately $20.2 million for calendar years 2025-2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive report. While the first revenue generation and reduced net loss are positive milestones, the significant 'going concern' warning and substantial liabilities temper enthusiasm, indicating continued financial challenges.

Positives

• Generated first-time revenue of $3,944,111 from the commercial launch of LYMPHIR in December 2025.
• Achieved a strong gross profit margin of approximately 80% on net product revenues.
• Reduced net loss by $1,125,136, from $6,659,205 in Q1 2025 to $5,534,069 in Q1 2026.
• Successfully raised $15.1 million in net proceeds from an equity offering in December 2025, increasing cash reserves.
• Paid off the outstanding milestone approval fee and accumulated interest to Eisai by December 15, 2025.
• Dr. Reddys waived the six-month commercial launch requirement for LYMPHIR, which was satisfied by the December 2025 launch.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern beyond May 2026 without additional capital.
• Reported a negative working capital of approximately $7.6 million as of December 31, 2025.
• Accumulated deficit reached $69,574,025 as of December 31, 2025.
• An $18.25 million balance of a milestone payment is still due to Dr. Reddys.
• Owes approximately $6.8 million to Eisai for other unpaid invoices.
• Has significant minimum purchase commitments for manufacturing and supply totaling approximately $20.2 million through 2027.

Risks

• Substantial doubt about the company's ability to continue as a going concern.
• Need for substantial additional funds and uncertainty regarding the ability to raise those funds on acceptable terms or at all.
• Uncertainty regarding the successful commercialization of LYMPHIR, including covering costs of licensing payments, manufacturing, and third-party services.
• Risk of not maintaining compliance with Nasdaq's continued listing requirements.
• Uncertainty regarding the ability of LYMPHIR or future product candidates to impact patient quality of life or achieve market acceptance.
• Risks that the anticipated benefits of the August 2024 reverse merger may not be fully realized or may take longer than expected.
• Challenges in procuring cGMP commercial-scale supply for products.
• Difficulty in obtaining, performing under, and maintaining financing and strategic agreements and relationships.
• Challenges in managing and growing the business and executing business and growth strategies.
• Difficulty in recruiting and retaining qualified management and technical personnel.
• Potential for competition from larger companies and development of competing products by others.

Future Outlook

The company expects to have sufficient funds to continue operations through May 2026 but will require substantial additional capital thereafter. It plans to continue relying on partial funding from Citius Pharma, raising capital through equity financings, and generating revenue from LYMPHIR sales. Citius Oncology has also retained Jefferies LLC to evaluate strategic alternatives to maximize shareholder value.

Management Comments

• Management believes that revenues will increase in the future as LYMPHIR gains market acceptance.

Industry Context

StockSavvy.ai notes that Citius Oncology's entry into the commercial phase with LYMPHIR for CTCL positions it in a niche but competitive oncology market. The successful launch and initial revenue generation are critical steps for a specialty biopharmaceutical company, especially given the high development costs and regulatory hurdles in the pharmaceutical industry. The reliance on external funding and the 'going concern' warning are common for early-commercial-stage biotech firms, highlighting the capital-intensive nature of drug development and commercialization.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for direct industry comparison.

Corporate Governance

Related Party Transactions

• Citius Pharma, Inc. (Nasdaq: CTXR) continues to partially fund Citius Oncology and owned approximately 78% of its outstanding common stock as of December 31, 2025.
• Citius Oncology and Citius Pharma are party to an amended and restated shared services agreement, under which Citius Pharma provides management and scientific services.
• During the three months ended December 31, 2025, Citius Pharma charged Citius Oncology $497,937 for general and administrative payroll, $480,000 for research and development payroll, and $27,939 for shared office space.
• Citius Pharma advanced $3,800,111 to Citius Oncology under a non-interest bearing, unsecured promissory note dated August 16, 2024, classified as a long-term liability.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future capital raises, but also potential for value creation if LYMPHIR commercialization is successful and strategic alternatives yield positive outcomes. Current shareholders of Citius Pharma (CTXR) also have significant indirect exposure.
• **Employees/Management:** Stock-based compensation is a significant component, aligning incentives. The need for additional capital and going concern warning could create uncertainty.
• **Customers (Specialty Distributors/Healthcare Providers):** The commercial launch of LYMPHIR provides a new treatment option for CTCL patients, with distribution through established channels.
• **Suppliers (CMOs):** The company has significant minimum purchase commitments with contract manufacturing organizations, ensuring supply but also creating financial obligations.
• **Creditors (Dr. Reddys, Eisai, Citius Pharma):** The company has substantial outstanding liabilities, including milestone payments and unpaid invoices, which are being managed through deferrals and payment schedules.

Next Steps

• Raise additional capital to support operations beyond May 2026.
• Continue efforts to generate revenue from sales of LYMPHIR and gain market acceptance.
• Citius Pharma and Citius Oncology are actively engaged in capital raising efforts.
• Jefferies LLC will continue evaluating strategic alternatives aimed at maximizing shareholder value.
• Complete two investigator-initiated immuno-oncology trials (both initiated) on or before the four-year anniversary of the definitive agreement with Dr. Reddys.

Key Dates

Recommendation

The company has achieved a significant milestone with its first revenue generation from LYMPHIR and has reduced its net loss. However, the explicit 'going concern' warning and substantial need for future capital, coupled with significant outstanding liabilities and purchase commitments, introduce considerable financial uncertainty. While the commercial launch is a positive step, the path to sustained profitability and financial stability remains challenging. An investor should 'hold' to observe the trajectory of LYMPHIR sales, the success of future capital raising efforts, and the outcome of strategic alternative evaluations before making a more definitive investment decision.

Keywords

Citius Oncology, CTOR, LYMPHIR, denileukin diftitox, CTCL, Cutaneous T-cell lymphoma, Oncology immunotherapy, Biopharmaceutical, SEC filing, 10-Q, Financial results, Going concern, Capital raise, Drug launch, Pharmaceutical industry, Biologics License Application, FDA approval